Development and Clinical Application of [11C]Verapamil-PET

• Status: Unknown status
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The major hypothesis explaining drug resistance is overexpression of p-glycoprotein at the target lesion. Based on several studies, p-glycoprotein (P-gp) has an important role in neurologic diseases, especially in drug resistant epilepsy. But there is no surrogate marker that can quantify the expression of P-gp because of the difficulty in measuring substances in the neurologic system and the lack of clinical trials. Here, the investigators use a novel non-invasive [11C] -verapamil Brain PET and SPAM analytic method as a surrogate marker for quantifying the expression of p-glycoprotein.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Cyclosporine; Cyclosporins; Verapamil

Criteria

Inclusion Criteria:

• Healthy controls ( age range 20-45 years)

• Patient age (> 15), diagnose as epilepsy

Exclusion Criteria:

• Subjects who take medicines that affect on the function of p-glycoproteins

• Pregnancy or subject who feed the breast milk

• Subjects who had severe renal disease or liver disease

• Subjects who need treated by immunosuppressant or take immunosuppressant